BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

PARIS, Sept 28 (Reuters) - Sanofi and Eli Lilly have reached a deal putting an end to a patent infringement lawsuit on Sanofi's Lantus SoloSTAR, Sanofi said in a statement on Monday. "The agreement ...

Sanofi announced today, at the 71st Scientific American Diabetes Association Sessions 2011, the results of three studies showing that people with diabetes using Sanofi insulins Lantus(R) and/or Apidra ...

A less-expensive version of the world's top-selling insulin, Sanofi's Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over patents for Lantus ...

PARIS, February 14 Sanofi-aventis announcedtoday that the Chicago Athenaeum Museum of Architecture and Design hasawarded a 2007 GOOD DESIGN(TM) Award for the new SoloSTAR(R) disposableinsulin ...

Sanofi has put off a biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering ...

Sanofi, the French drugmaker settled a lawsuit over patents for Lantus SoloStar, its once-daily insulin in a pen-like injector on September 28. Sanofi's Lantus is a less expensive version of the world ...

Levemir and Lantus are both long-acting injectable insulins that can be used for long-term management of diabetes. Insulin is a hormone that is naturally produced in the body by the pancreas. It helps ...

HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter ...